|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pashos CL, Botteman MF, Laskin BL and
Redaelli A: Bladder cancer: Epidemiology, diagnosis, and
management. Cancer Pract. 10:311–322. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeegers MP, Tan FE, Dorant E and van Den
Brandt PA: The impact of characteristics of cigarette smoking on
urinary tract cancer risk: A meta-analysis ofepidemiologic studies.
Cancer. 89:630–639. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khadjavi A, Mannu F, Destefanis P,
Sacerdote C, Battaglia A, Allasia M, Fontana D, Frea B, Polidoro S,
Fiorito G, et al: Early diagnosis of bladder cancer through the
detection of urinary tyrosine-phosphorylated proteins. Br J Cancer.
113:469–475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murakami Y, Nobukuni T, Tamura K, Maruyama
T, Sekiya T, Arai Y, Gomyou H, Tanigami A, Ohki M, Cabin D, et al:
Localization of tumor suppressor activity important in nonsmall
cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci USA.
95:8153–8158. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuramochi M, Fukuhara H, Nobukuni T, Kanbe
T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura
T, et al: TSLC1 is a tumor-suppressor gene in human non-small-cell
lung cancer. Nat Genet. 27:427–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shingai T, Ikeda W, Kakunaga S, Morimoto
K, Takekuni K, Itoh S, Satoh K, Takeuchi M, Imai T, Monden M and
Takai Y: Implications of nectin-like molecule-
2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and
transmembrane protein localization in epithelial cells. J Biol
Chem. 278:35421–35427. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamada D, Yoshida M, Williams YN, Fukami
T, Kikuchi S, Masuda M, Maruyama T, Ohta T, Nakae D, Maekawa A, et
al: Disruption of spermatogenic cell adhesion and male infertility
in mice lacking TSLC1/IGSF4, animmunoglobulin superfamily cell
adhesion molecule. Mol Cell Biol. 26:3610–3624. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ito T, Shimada Y, Hashimoto Y, Kaganoi J,
Kan T, Watanabe G, Murakami Y and Imamura M: Involvement of TSLC1
in progression of esophageal squamous cell carcinoma. Cancer Res.
63:6320–6326. 2003.PubMed/NCBI
|
|
11
|
You Y, Zhang J, Li Y, Li Y, Shi G, Ma L
and Wei H: CADM1/TSLC1 inhibits melanoma cell line A375 invasion
through the suppression of matrix metalloproteinases. Mol Med Rep.
10:2621–2626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He G, Lei W, Wang S, Xiao R, Guo K, Xia Y,
Zhou X, Zhang K, Liu X and Wang Y: Overexpression of tumor
suppressor TSLC1 by a survivin-regulated oncolytic adenovirus
significantly inhibits hepatocellular carcinoma growth. J Cancer
Res Clin Oncol. 138:657–670. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang G, He W, Cai M, Luo F, Kung H, Guan
X, Zeng Y and Xie D: Loss/down-regulation of tumor suppressor in
lung cancer 1 expression is associated with tumor progression and
is a biomarker of poor prognosis in ovarian carcinoma. Int J
Gynecol Cancer. 21:486–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heller G, Geradts J, Ziegler B, Newsham I,
Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer
W, Depisch D, et al: Downregulation of TSLC1 and DAL-1 expression
occurs frequently in breast cancer. Breast Cancer Res Treat.
103:283–291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jansen M, Fukushima N, Rosty C, Walter K,
Altink R, Heek TV, Hruban R, Offerhaus JG and Goggins M: Aberrant
methylation of the 5′ CpG island of TSLC1 is common in pancreatic
ductal adenocarcinoma and is first manifest in high-grade PanlNs.
Cancer Biol Ther. 1:293–296. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takahashi Y, Iwai M, Kawai T, Arakawa A,
Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F and
Murakami Y: Aberrant expression of tumor suppressors CADM1 and 4.1B
in invasive lesions of primary breast cancer. Breast Cancer.
19:242–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lei W, Liu HB, Wang SB, Zhou XM, Zheng SD,
Guo KN, Ma BY, Xia YL, Tan WS, Liu XY and Wang YG: Tumor suppressor
in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic
adenovirus exerts specific antitumor actions in a mouse model. Acta
Pharmacol Sin. 34:531–540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu B, Di W, Wang H, Ma H, Li J and Zhang
Q: Tumor suppressor TSLC1 is implicated in cell proliferation,
invasion and apoptosis in laryngeal squamous cell carcinoma by
regulating Akt signaling pathway. Tumour Biol. 33:2007–2017. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen K, Wang G, Peng L, Liu S, Fu X, Zhou
Y, Yu H, Li A, Li J, Zhang S, et al: CADM1/TSLC1 inactivation by
promoter hypermethylation is a frequent event in colorectal
carcinogenesis and correlates with late stages of the disease. Int
J Cancer. 128:266–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fukuhara H, Kuramochi M, Fukami T,
Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T,
Shuin T, et al: Promoter methylation of TSLC1 and tumor suppression
by its gene product in human prostate cancer. Jpn J Cancer Res.
93:605–609. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ochiai H, Takenobu H, Nakagawa A,
Yamaguchi Y, Kimura M, Ohira M, Okimoto Y, Fujimura Y, Koseki H,
Kohno Y, et al: Bmi1 is a MYCN target gene that regulates
tumorigenesis through repression of KIF1Bbeta and TSLC1 in
neuroblastoma. Oncogene. 29:2681–2690. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lung HL, Cheung AK, Xie D, Cheng Y, Kwong
FM, Murakami Y, Guan XY, Sham JS, Chua D, Protopopov AI, et al:
TSLC1 is a tumor suppressor gene associated with metastasis in
nasopharyngeal carcinoma. Cancer Res. 66:9385–9392. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hui AB, Lo KW, Kwong J, Lam EC, Chan SY,
Chow LS, Chan AS, Teo PM and Huang DP: Epigenetic inactivation of
TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 38:170–178.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sacristan R, Gonzalez C, Fernández-Gómez
JM, Fresno F, Escaf S and Sánchez-Carbayo M: Molecular
classification of non-muscle-invasive bladder cancer (pTa
low-grade, pT1 low-grade, and pT1 high-grade subgroups) using
methylation of tumor-suppressor genes. J Mol Diagn. 16:564–572.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agundez M, Grau L, Palou J, Algaba F,
Villavicencio H and Sanchez-Carbayo M: Evaluation of the
methylation status of tumour suppressor genes for predicting
bacillus Calmette-Guérin response in patients with T1G3 high-risk
bladder tumours. Eur Urol. 60:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Casadio V, Molinari C, Calistri D, Tebaldi
M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R,
Amadori D and Zoli W: DNA Methylation profiles as predictors of
recurrence in non muscle invasive bladder cancer: An MS-MLPA
approach. J Exp Clin Cancer Res. 32:942013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hellwinkel OJ, Kedia M, Isbarn H, Budäus L
and Friedrich MG: Methylation of the TPEF- and PAX6-promoters is
increased in early bladder cancer and in normal mucosa adjacent to
pTa tumours. BJU Int. 101:753–757. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eble JS, Epstein JI, Sesterhenn IA and
Sauter G: Pathology and genetics of tumours of the urinary system
and male genital organs. World Health Organization Classification
of Tumours Lyon: IARC Press; 2004
|
|
29
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. (7th). (Weinheim).
Wiley. 2009.
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mao X, Seidlitz E, Truant R, Hitt M and
Ghosh HP: Re-expression of TSLC1 in a non-small-cell lung cancer
cell line induces apoptosis and inhibits tumor growth. Oncogene.
23:5632–5642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qin L, Zhu W, Xu T, Hao Y, Zhang Z, Tian Y
and Yang D: Effect of TSLC1 gene on proliferation, invasion and
apoptosis of human hepatocellular carcinoma cell line HepG2. J
Huazhong Univ Sci Technolog Med Sci. 27:535–537. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cardif RD: Epithelial to mesenchymal
transition tumors: Fallacious or snail's pace? Clin Cancer Res.
11:8534–8537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liang W, Hao Z, Han JL, Zhu DJ, Jin ZF and
Xie WL: CAV-1 contributes to bladder cancer progression by inducing
epithelial-to-mesenchymal transition. Urol Oncol. 32:855–863. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wan F, Cheng C, Wang Z, Xiao X, Zeng H,
Xing S, Chen X, Wang J, Li S, Zhang Y, et al: SATB1 overexpression
regulates the development and progression in bladder cancer through
EMT. PLoS One. 10:e01175182015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao J, Dong D and Sun L, Zhang G and Sun
L: Prognostic significance of the epithelial-to-mesenchymal
transition markers e-cadherin, vimentin and twist in bladder
cancer. Int Braz J Urol. 40:179–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Geng J, Fan J, Ouyang Q, Zhang X, Zhang X,
Yu J, Xu Z, Li Q, Yao X, Liu X and Zheng J: Loss of PPM1A
expression enhances invasion and the epithelial-to-mesenchymal
transition in bladder cancer by activating the TGF-β/Smad signaling
pathway. Oncotarget. 5:5700–5711. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chhabra R: Cervical cancer stem cells:
Opportunities and challenges. J Cancer Res Clin Oncol.
141:1889–1897. 2015. View Article : Google Scholar : PubMed/NCBI
|
